Bleomycin/cisplatin/etoposide

Bleomycin/cisplatin/etoposide Reactions 1680, p71 - 2 Dec 2017 Neutropenia, anaemia and thrombocytopenia: 2 case reports A 16-year-old girl and a 19-year-old woman were described, who developed neutropenia and anaemia or neutropenia, anaemia and thrombocytopenia each, during treatment with bleomycin, cisplatin and etoposide [not all outcomes stated; durations of treatments to reactions onsets not stated]. Patient 1: A 16-year-old girl was diagnosed with stage IIIc small cell ovarian cancer, and was initiated on chemotherapy with the BEP regimen, which consisted of bleomycin, cisplatin and etoposide [routes and dosages not stated]. She received three cycles of chemotherapy and subsequently developed grade 4 afebrile neutropenia and grade 1 anaemia. Her disease progressed, and her regimen was changed to irinotecan and doxorubicin-liposomal. She showed disease progression, and died 6 months after the initial diagnosis of small cell ovarian cancer. Patient 2: A 19-year-old woman was diagnosed with small cell ovarian cancer, and was initiated on chemotherapy with the BEP regimen, which consisted of bleomycin, cisplatin and etoposide. She received two cycles of chemotherapy and subsequently developed grade 4 neutropenia, grade 2 anaemia and grade 4 thrombocytopenia. She was treated with unspecified granulocyte colony stimulating factors [GCSF] and erythropoietin. Her anaemia responded well to erythropoietin treatment. She later received three more cycles of etoposide and cisplatin. Her disease progressed to the liver and she was initiated on treatment with irinotecan and doxorubicin- liposomal. She died 7 months after the initial diagnosis of small cell ovarian cancer. Author comment: "[C]hemotherapy with BEP (bleomycin, etoposide, cisplatin), with relatively good tolerance, beside hematologic toxicity (afebrile gr IV neutropenia, gr I anemia)." "[R]eceived 2 cycles of BEP, with moderate tolerance (episode of gr IV neutropenia that demanded the prophylactic use of GCSF, gr II anemia that responded well to rh-EPO, gr IV thrombocytopenia)." Rovithi M, et al. Small cell ovarian cancer in adolescents: Report of two cases and review of the literature. Case Reports in Medicine 2011: Jan 2011. Available from: URL: http://doi.org/10.1155/2011/749516 - Greece 803283919 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Bleomycin/cisplatin/etoposide

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/bleomycin-cisplatin-etoposide-woym9KrN3G
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39002-y
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p71 - 2 Dec 2017 Neutropenia, anaemia and thrombocytopenia: 2 case reports A 16-year-old girl and a 19-year-old woman were described, who developed neutropenia and anaemia or neutropenia, anaemia and thrombocytopenia each, during treatment with bleomycin, cisplatin and etoposide [not all outcomes stated; durations of treatments to reactions onsets not stated]. Patient 1: A 16-year-old girl was diagnosed with stage IIIc small cell ovarian cancer, and was initiated on chemotherapy with the BEP regimen, which consisted of bleomycin, cisplatin and etoposide [routes and dosages not stated]. She received three cycles of chemotherapy and subsequently developed grade 4 afebrile neutropenia and grade 1 anaemia. Her disease progressed, and her regimen was changed to irinotecan and doxorubicin-liposomal. She showed disease progression, and died 6 months after the initial diagnosis of small cell ovarian cancer. Patient 2: A 19-year-old woman was diagnosed with small cell ovarian cancer, and was initiated on chemotherapy with the BEP regimen, which consisted of bleomycin, cisplatin and etoposide. She received two cycles of chemotherapy and subsequently developed grade 4 neutropenia, grade 2 anaemia and grade 4 thrombocytopenia. She was treated with unspecified granulocyte colony stimulating factors [GCSF] and erythropoietin. Her anaemia responded well to erythropoietin treatment. She later received three more cycles of etoposide and cisplatin. Her disease progressed to the liver and she was initiated on treatment with irinotecan and doxorubicin- liposomal. She died 7 months after the initial diagnosis of small cell ovarian cancer. Author comment: "[C]hemotherapy with BEP (bleomycin, etoposide, cisplatin), with relatively good tolerance, beside hematologic toxicity (afebrile gr IV neutropenia, gr I anemia)." "[R]eceived 2 cycles of BEP, with moderate tolerance (episode of gr IV neutropenia that demanded the prophylactic use of GCSF, gr II anemia that responded well to rh-EPO, gr IV thrombocytopenia)." Rovithi M, et al. Small cell ovarian cancer in adolescents: Report of two cases and review of the literature. Case Reports in Medicine 2011: Jan 2011. Available from: URL: http://doi.org/10.1155/2011/749516 - Greece 803283919 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off